德国

我们是谁

  • 4 月 5, 2022
    An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
  • 4 月 5, 2022
    为孤立、不可切除的结直肠肝转移患者进行活体肝移植和两期肝切除术
  • 4 月 5, 2022
    KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究(KRYSTAL-10)
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Repotrectinib(TPX-0005)对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 4 月 5, 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
  • 4 月 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)